Phaseline

Companies › PT. JES Kasih Nusantara Sejahterah

PT. JES Kasih Nusantara Sejahterah: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Autologous Dendritic Cell (Immunotherapy Nusantara: DCL)
Autologous dendritic cells matured ex vivo with SARS-CoV-2 S protein, co-administered with
–Phase 1Diabetic Kidney Disease (DKD)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06866158Autologous Dendritic Cell (Immunotherapy Nusantara: DCL)Phase 1Diabetic Kidney Disease (DKD)Metabolic and endocrineAug 2024

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.